drugset / Trial / NCT06507059
Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.
Timeline
- Start
- 2024-07-19
- Primary completion
- 2025-07-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | 600 mg | Other |
| Subject | Rilpivirine | Small molecule | 900 mg | Other |